SCHEMBL6988786

SCHEMBL6988786

CON(C)C(=O)c1ccc(Cl)c(I)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.44
SLC6A3 Q01959 1/20 0.44
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
MCHR1 Q99705 1/20 0.36
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
HPGD P15428 1/20 0.35
TTR P02766 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655175 0.85 SLC6A3 (0.54) MLYCDSLC6A3MEN1KMT2APKM
SCHEMBL5775088 0.82 MLYCD (0.45) MLYCDMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4097869 0.82 MLYCD (0.45) MLYCDSLC6A3MEN1KMT2APKM
SCHEMBL2787613 0.82 ESR1 (0.47) MLYCDMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13724877 0.82 MLYCD (0.45) MLYCDSLC6A3MEN1KMT2APKM
SCHEMBL5604944 0.81 CYP1A2 (0.44) MLYCDSLC6A3MEN1KMT2ARAB9A
SCHEMBL5775166 0.81 MLYCD (0.48) MLYCDSLC6A3MEN1KMT2APKM
SCHEMBL185480 0.81 MEN1 (0.48) MLYCDSLC6A3MEN1KMT2APKM
SCHEMBL13002606 0.79 MLYCD (0.45) MLYCDSLC6A3SMN1; SMN2HSP90AA1HSP90AB1
SCHEMBL8988251 0.79 MLYCD (0.45) MLYCDSLC6A3MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 MLYCD 2194/4885SLC6A3 3408/4885MEN1 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.